Transforming Early CKD Detection
into Proactive Clinical Action
From passive data to proactive care — reducing the global dialysis burden through AI-assisted screening, patient education, and pathway optimisation.
AI-Powered Clinical Intelligence — Every step, from risk stratification and screening to patient education and outcome optimisation, is supported by SafeSoul AI Lite — integrated directly into existing EMR systems with no major system changes required.
Who We Are, What We Do & Why It Matters
SafeSoul™ Ltd is a UK-based, clinically-led healthcare innovation company. We don't create new data — we make existing data work harder for patients and systems.
Who We Are
UK-based Healthcare Innovation Company
Clinically Led by a Consultant Nephrologist
3+ Years in Development
HMRC Registered · SafeSoul Ltd.
What We Do
Turn routine patient data into AI-powered risk alerts
Enable early CKD identification in primary care settings
Support continuous AI monitoring & pathway optimisation
EMR Integration — no major system changes needed
Why It Matters
Reduce late-stage kidney disease and ESRD progression
Cut dialysis & hospital demand on healthcare systems
Improve patient outcomes at dramatically lower cost
Expand access to nephrology care in underserved regions
"We don't create new data — we make existing data work." · Turning routine clinical information into life-saving risk alerts, powered by AI, guided by specialist nephrologists.
Meet the Founder & Director
SafeSoul™ is led by one of the most published nephrologists in the field — combining decades of clinical practice with global public health expertise and AI-driven innovation.
Consultant Nephrologist & Public Health Specialist
"Early detection is not a clinical luxury — it is a healthcare system imperative."
Dr. Ch. M. Junaid Nazar is a dedicated and compassionate Consultant Nephrologist with specialist expertise in Chronic Kidney Disease, End-Stage Renal Disease, Hypertension, and Kidney Transplantation. As CEO and Founder of SafeSoul™ Ltd, he leads the design and global deployment of AI-assisted CKD prevention programmes across the UK, Caribbean, and international healthcare systems.
With a career spanning clinical nephrology, public health, and academic research, Dr. Junaid has published over 101 research articles in peer-reviewed journals including the Journal of Nephropharmacology, Journal of Renal Injury Prevention, and Endocrinology & Metabolic Syndrome — available on PubMed and Google Scholar, cited by 497+ researchers worldwide.
He holds the Head of Nephrology position at the World Academy of Medical Sciences (WAMS) since 2016, serves on multiple international editorial boards, and was trained at the University of Buckingham, University of Brighton, and the University of Bedfordshire — all in the United Kingdom.
Academic Qualifications
Early CKD Detection & Integrated Care Algorithm
SafeSoul's AI-powered algorithm connects four pillars of care — from first screening through to personalised outcome optimisation — all coordinated through a single integrated system.
Screening & Risk Stratification
Identify at-risk individuals from existing health data
uACR & eGFR blood/urine tests to detect early CKD markers
AI analyses patient records to flag high-risk individuals automatically
Diabetes & hypertension patients prioritised for first-line screening
No new data collection — AI works with existing EMR records
Diagnosis & Monitoring
Confirm CKD stage and track progression over time
eGFR and ACR tests confirm diagnosis and CKD staging (1–5)
AI-generated risk stratification reports for clinician review
Continuous monitoring with automated alerts on deterioration
Nephrologist-led clinical oversight at every decision point
Connecting all four pillars through a single AI intelligence layer — integrated with your existing EMR
Integrated CKD Care
Coordinated primary care, diagnostics and specialist nephrology
GP-led management with direct nephrology specialist input
AI-personalised patient education on diet, hydration, medication
Low-cost medications (~$500–$1,500/year) for early-stage CKD
Patient adherence tracking and automated follow-up scheduling
Outcome Optimisation
Personalised care plans to prevent progression and reduce complications
AI continuously refines care pathways based on patient outcomes
Dialysis prevention targets: 3–5 patients = $240K–$600K annual savings
Cardiovascular risk reduction through early renal protection
Population-level data fed back to improve system-wide programme design
Our Clinical Programmes
Four core service pillars — all AI-assisted, all clinically-led, all designed to keep doctors in control and patients healthier for longer.
Patient Education Series
Structured education programmes supporting CKD awareness, dietary guidance, and long-term disease management — AI-personalised for each patient's stage, literacy level, and cultural background.
Cost Impact Screening
AI-driven early CKD screening delivers dramatic cost savings. Identifying high-risk patients before Stage 3 progression is the single highest-ROI intervention in kidney health economics.
Global Programme Development
SafeSoul™ is actively engaging healthcare systems across the Caribbean (BVI, Turks & Caicos) and international regions, deploying AI-integrated nephrology prevention where it is needed most.
Regulatory Positioning
SafeSoul™ Ltd (UK) is engaged in ongoing regulatory alignment processes supporting compliant international expansion — with AI tools built to meet NICE guidelines and international clinical governance standards.
The True Cost of Late CKD Detection
The BVI health system is a compelling example of why early CKD screening is not new spending — it is cost avoidance at a massive scale. SafeSoul's model proves this with real numbers.
Late Detection — ESRD Costs
What happens when CKD goes undetected until dialysis
Dialysis: $80K–$120K per year
Emergency Admission: $5K–$15K
AV Fistula Surgery: $5K–$10K
Temporary Catheter: $1.5K–$3K
Annual Medications: $10K–$20K
Most cost occurs AFTER it is too late
Early Detection — CKD Costs
What prevention looks like with the SafeSoul model
uACR & eGFR Screening: $10–$25
Annual Care Plan: $500–$1,500
GP-Led Management with AI Support
Risk Stratification & Patient Education
Low-cost medications for early-stage control
Linear cost vs exponential cost of late treatment
The Global Scale of the CKD Challenge
The evidence for early intervention is overwhelming. These are the numbers that make SafeSoul™'s mission not just a clinical priority — but an economic imperative for every healthcare system.
Four Pillars of Kidney Health
SafeSoul's patient education programmes are built around these evidence-based pillars — ensuring patients understand how to protect their kidneys and live longer, healthier lives.
Pilot Study Timeline
SafeSoul™'s CKD prevention pilot follows a rigorous 12-week structured methodology — from preparation through to report and presentation — ensuring evidence-based programme design.
"Every patient who avoids dialysis represents not just a clinical success — it is a life preserved in dignity, and a healthcare system spared an immense and avoidable burden."
Partner With SafeSoul™
Whether you are a healthcare system, hospital, government body, or nephrology department — we welcome conversations about bringing the SafeSoul™ CKD prevention programme to your population.
SafeSoul™ Ltd · United Kingdom
We are actively engaging with healthcare systems across the Caribbean, UK, and international regions. Reach out to discuss a pilot programme, regulatory alignment, or clinical partnership.
UK Registered
SafeSoul™ Ltd registered in England & Wales
HMRC Registered
Compliant with UK financial and tax regulations
Clinically Led
Directed by a Consultant Nephrologist with 101+ publications
AI-Powered
SafeSoul AI Lite — EMR integrated, no system overhaul needed
3+ Years Development
Robust, tested programme design and clinical methodology
Global Reach
Active in UK, Caribbean and international healthcare systems